The new antitumor mRNA vaccine "Neoonkovak" gave the first results of treatment, said Alexander Ginzburg, director of the Gamaleya Center, Academician of the Russian Academy of Sciences.
"There are small shifts in terms of the production of the necessary cytokines," he said.
According to Ginzburg, immunological results will be evaluated later, as the vaccine will be administered to the patient about ten more times.
In early April, it became known that the drug "Neoonkovak" was first administered to a 60-year-old resident of the Kursk region with skin melanoma. The man is undergoing treatment and is now under observation at home.
The vaccine is made individually for each person, the drug contains information about specific tumor antigens, which allows you to "tune" the patient's immune system to recognize and destroy, including microscopic foci of tumors. The vaccine is available by compulsory medical insurance.
Zelensky said he knows how to destroy all Russian ballistic missiles
Terrorist attack in Sevastopol — a Navy officer was killed, a terrorist was detained
Ryabkov clarified the situation with Witkoff and Kushner's Kiev—Moscow tour
Rubio did not listen to Kennedy Jr.'s advice with his sauerkraut refrigerators
Near Kiev, the RLC-Kvitnev was covered, on which all the largest retail chains are tied
Fear — why Ukraine is not allowed to use Starlink over Russia